That is very important, because the method a protein in the body folds determines if a pharmaceutical will have the ability to bind to that protein and be effective. In other words, we have to know how these proteins fold if we want a drug to work. Historically, this has actually been a trial-and-error process (jeff brown predictions for 2021). Now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it much simpler to develop drugs that do what they're developed to do. This was an advancement almost no one noticed. But it's going to have extensive implications for curing disease. I predict that Alpha, Fold will be 98% accurate by the end of 2021.
And, of course, there will be lots of investment chances in this space, too. Shifting subjects It's going to be a great year for bitcoin. I'm bullish on it in 2021 (jeff brown 2020 predictions). That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be amazed if it drew back perhaps substantially before going greater - social media. I've been covering bitcoin for a very long time now. Among the first research study reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial suggestion, I entitled my report "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time. We were primarily educating readers. But that's not the big concern any longer. Now we're seeing institutional cash finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, niche enterprise. Mass, Mutual is a relied on 170-year-old organization. So think of that. In five years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
Which's a huge factor I'm bullish on it this year. brownstone research. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus offer prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous yearly record by 43%. I predict 2021 will be another record year in IPOs. There are numerous great private companies on the edge of striking the general public markets And I've been dealing with a brand-new method for you to invest even before these companies go public.
This chance has actually been developing over the last couple of years. I can't wait to tell you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to discover all the information. Go right here to schedule your area free of charge.
Emma Walsh here, managing editor of the Journal. Regular Diary readers know that tech isn't our usual beat (second wave). And when it pertains to tech investing, we leave it to the professionals. Fortunately, we have numerous such experts in our Rolodex. Our colleague Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing professionals we know (bleeding edge). In truth, he had a number of triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the big picture and anticipate what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and much more. These trends are experiencing rapid growth and producing unbelievable chances for financiers. I wish to make certain all our readers are prepared for what's next. And with that in mind, let me draw the photo of what I see being available in the next 12 months Our brand-new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. toxic tech 5 tech darlings. However regardless of what numerous readers may believe, this is a pattern that's simply starting. Even though the COVID-19 pandemic disrupted supply chains in 2015, an excellent 250 million 5G-enabled devices were still offered.
And all of this ultimately caused Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (biotech stocks). Losing two months of manufacturing and sales really impacts the number of 5G gadgets are offered in the calendar year. When you think about all of that, selling 250 million systems is remarkable. More notably, the hold-ups brought on by the pandemic developed a ton of suppressed need. Which demand is now going to be pushed into 2021. In fact, I forecast that more than 500 million 5G gadgets will be shipped in 2021 - legacy report prediction. And that's not my only 5G prediction When I've discussed 5G in the past, I've explained its three different phases.
In Stage Two, 5G gadgets go on sale. 5G phones and other products start to reach consumers. And in Stage 3, 5G services start to be provided (jeff brown biotech pick). That's when we start to see applications operating on 5G networks. Think about things like huge multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my 2nd 5G forecast for 2021 is that we will start Stage Three by this summer season. This starts something of a virtuous cycle: Many people do not really appreciate the technology. But they will care if there are exciting applications that can only be accessed with a 5G phone.
That results in more 5G apps being developed. In fact, 5G is going to open up a suite of unbelievable applications: self-driving automobiles, the Internet of Things, robotic surgery, and more. All of these technologies require 5G. The investment opportunities moving forward will be massive. Stepping far from 5G, the next important innovation I foresee in 2021 is CRISPR hereditary editing. CRISPR represents "clustered frequently interspaced short palindromic repeat." It's a mouthful. But it's one of the most amazing developments in biotechnology. At a high level, CRISPR is an innovation that can modify our genetic makeup as if it were software.
The program can crash or not work correctly. CRISPR uses a similar concept however with our hereditary code. "Typos" in our genome can lead to disease. CRISPR can correct these "typos." For many years, CRISPR was mostly a specific niche technology that wasn't well comprehended. And throughout that time, there were truly only three companies running in this space. But things are changing. CRISPR is no longer simply theoretical. We're seeing actual results. We're treating diseases and seeing that this innovation just works. And as an outcome, a "2nd crop" of early-stage CRISPR companies is going public and providing unbelievable returns. This whole market is effectively a greenfield opportunity.
There's room for numerous business to exist in this space. jeff brown investor prediction. And there will be more. That's my forecast for CRISPR in 2021. I forecast that two or 3 more hereditary modifying business will hold their IPOs. Sticking with biotechnology, we are seeing remarkable things happening at the convergence of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its latest Alpha, Fold software application can accurately predict the folding of a protein based entirely on its amino acid series with 92. 4% precision. That is essential since the method a protein in the human body folds determines if a pharmaceutical will have the ability to bind to that protein and work.
Historically, this has actually been a trial-and-error process. And now, Alpha, Fold can forecast protein folding with 92. 4% accuracy. That's going to make it a lot easier to produce drugs that do what they're developed to do. And here's my next forecast. I predict that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but a number of drug treatments produced using this innovation. This was among those advancements that practically no one discovered. But it's going to have profound ramifications for treating disease. And, obviously, there will be a lot of financial investment opportunities in this area, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be shocked if it pulled back possibly considerably prior to going greater. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever released was on bitcoin - biotech stocks. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anyone who followed my recommendation. However at the time of that preliminary recommendation, I entitled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But nobody is asking that concern anymore. Now, we're seeing institutional cash finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. genetic sequencing companies jeff brown. Mass, Mutual is a 150-year-old organization. So think of that. In five years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus offer forecast In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown deserves about $27. 5 million and declares the info depends on date since February 2021, but we could not individually confirm this claim. Offered Jeff Brown's past, he likely has a substantial net worth, however we can't hammer down a precise figure at this moment. Brown is best known for his sage-like ability to pick winning innovation stocks. He invested more than 25 years looking into technology companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's comprehensive experience provides him an excellent viewpoint on the market. He's always on the hunt for brand-new chances, and he shares much of his finest picks in the Near Future Report.
That's high praise, however it's not ridiculously reasoned. Brown has an exceptional credibility as a stock-picker, and he successfully anticipated a few of the biggest financial events of the previous twenty years. Although he does not appear to launch his choices to the public, the service's success is a direct indicator of Brown's stock-picking expertise. No one on Wall Street gets it best each time, however Jeff Brown's precise forecasts have actually made him legions of dedicated followers. That states a lot about his ability. The Future Report is published by Brownstone Research study, a popular monetary research study publisher. Brownstone Research study uses numerous research services with a wide array of specializations - artificial intelligence.
The company is also associated with Bonner & Partners, another well-respected research study publisher - black sea. On its website, Brownstone says its mission is to provide retail investors with professional-grade research: "For too long, the best financial investment research study has not been readily available to private financiers. It has been usually reserved for investment banks, hedge funds, private equity, and high-net-worth customers. genetic sequencer stock jeff brown. The objective of Brownstone Research is to make that kind of exclusive research offered to any financiers wanting to acquire an edge in the markets. The goal is easy to provide unique and profitable financial investment research discovered nowhere else." -Brownstone Research site excerpt from the Jeff Brown is the founder of Brownstone Research study, and he also functions as the firm's Chief Financial investment Expert.
With Brown assisting the ship, Brownstone Research is a powerhouse publisher with lots to use its clients. After decades of constant success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a household name throughout the majority of America. If you understand even a little bit about the market, you understand that he has a reputation as a King Midas of sorts. biotech stocks. Whatever he touches relies on gold! Jeff is aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big project.
In fact, Brown thinks S.A.V. last week. might be "the greatest trend of the 2020s, and he's not alone. Check out these quotes from other popular S.A.V. bulls: Elon's next huge act will be weding 2 advanced technologies: expert system and electrical vehicles. Musk hopes the mix will assist him develop the first fully-autonomous, self-driving cars ever. It's nothing except the automotive industry's Holy Grail. As you understand, electrical lorries and self-driving vehicle stocks have been big this year, however the Wall Street machine has actually been huge on hype without much concrete result. Regardless of a drastic increase in competitors over the past couple of years, Brown still thinks Musk has the best possibility of putting it all together.
tech could be the magic string that connects it all together. S.A.V. means Shared Autonomous Automobile, and it could be the future of transport. Essentially, this innovation would allow you to lease your car as an autonomous, self-driving taxi when you're not utilizing it. You merely get out of the automobile and press a button on an app that tells the cars and truck to "join the fleet." Next thing you know, you're unwinding on your sofa while your vehicle shuttles ride-sharers around town. Most importantly, you get to keep a hefty portion of the revenues. It sounds insane, however it could be closed than you think.